Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell Therapeutics
Pharma
FDA turmoil compounds challenges for cell and gene therapy field
To innovators in the cell and gene therapy field, Peter Marks’ exit from the FDA means losing a seasoned regulator and key ally.
Angus Liu
Apr 2, 2025 3:16pm
J&J, Legend to invest $150M in Belgium cell therapy facility
Mar 12, 2025 2:15pm
BMS buys cell therapy partner 2seventy bio for $286M
Mar 11, 2025 10:12am
BMS angles Breyanzi for another blood cancer
Feb 10, 2025 9:50am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
Sep 25, 2024 10:52am
